Cargando…
Screening for Cushing’s Syndrome in Obese Patients
OBJECTIVES: The aim of this study was to examine the frequency of Cushing’s syndrome (CS) in obese patients devoid of specific clinical symptoms of Cushing’s syndrome. METHODS: A total of 150 obese patients (129 female, 21 male; mean age 44.41 ± 13.34 yr; mean BMI 35.76 ± 7.13) were included in the...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815288/ https://www.ncbi.nlm.nih.gov/pubmed/20126340 http://dx.doi.org/10.1590/S1807-59322010000100003 |
_version_ | 1782177013504671744 |
---|---|
author | Tiryakioglu, Ozay Ugurlu, Serdal Yalin, Serap Yirmibescik, Sibel Caglar, Erkan Yetkin, Demet Ozgil Kadioglu, Pinar |
author_facet | Tiryakioglu, Ozay Ugurlu, Serdal Yalin, Serap Yirmibescik, Sibel Caglar, Erkan Yetkin, Demet Ozgil Kadioglu, Pinar |
author_sort | Tiryakioglu, Ozay |
collection | PubMed |
description | OBJECTIVES: The aim of this study was to examine the frequency of Cushing’s syndrome (CS) in obese patients devoid of specific clinical symptoms of Cushing’s syndrome. METHODS: A total of 150 obese patients (129 female, 21 male; mean age 44.41 ± 13.34 yr; mean BMI 35.76 ± 7.13) were included in the study. As a first screening step, we measured 24-h urinary free cortisol (UFC). An overnight 1-mg dexamethasone suppression test was also performed on all patients. Urinary free cortisol levels above 100 μg/24 h were considered to be abnormal. Suppression of serum cortisol <1.8 μg/dL after administration of 1 mg dexamethasone was the cut-off point for normal suppression. The suppression of the serum cortisol levels failed in all of the patients. RESULTS: Measured laboratory values were as follows: ACTH, median level 28 pg/ml, interquartile range (IQR) 14–59 pg/ml; fasting glucose, 100 (91–113) mg/dL; insulin, 15.7 (7.57–24.45) mU/ml; fT(4), 1.17 (1.05–1.4) ng/dL; TSH, 1.70 (0.91–2.90) mIU/L; total cholesterol, 209 (170.5–250) mg/dL; LDL-c, 136 (97.7–163) mg/dL; HDL-c, 44 (37.25–50.75) mg/dL; VLDL-c, 24 (17–36) mg/dL; triglycerides, 120.5 (86–165) mg/dL. The median UFC level of the patients was 30 μg/24 h (IQR 16–103). High levels of UFC (>100 μg/24 h) were recorded in 37 patients (24%). Cushing’s syndrome was diagnosed in 14 of the 150 patients (9.33%). Etiologic reasons for Cushing’s syndrome were pituitary microadenoma (9 patients), adrenocortical adenoma (3 patients), and adrenocortical carcinoma (1 patient). CONCLUSION: A significant proportion (9.33%) of patients with simple obesity were found to have Cushing’s syndrome. These findings argue that obese patients should be routinely screened for Cushing’s syndrome. |
format | Text |
id | pubmed-2815288 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo |
record_format | MEDLINE/PubMed |
spelling | pubmed-28152882010-02-02 Screening for Cushing’s Syndrome in Obese Patients Tiryakioglu, Ozay Ugurlu, Serdal Yalin, Serap Yirmibescik, Sibel Caglar, Erkan Yetkin, Demet Ozgil Kadioglu, Pinar Clinics (Sao Paulo) Clinical Science OBJECTIVES: The aim of this study was to examine the frequency of Cushing’s syndrome (CS) in obese patients devoid of specific clinical symptoms of Cushing’s syndrome. METHODS: A total of 150 obese patients (129 female, 21 male; mean age 44.41 ± 13.34 yr; mean BMI 35.76 ± 7.13) were included in the study. As a first screening step, we measured 24-h urinary free cortisol (UFC). An overnight 1-mg dexamethasone suppression test was also performed on all patients. Urinary free cortisol levels above 100 μg/24 h were considered to be abnormal. Suppression of serum cortisol <1.8 μg/dL after administration of 1 mg dexamethasone was the cut-off point for normal suppression. The suppression of the serum cortisol levels failed in all of the patients. RESULTS: Measured laboratory values were as follows: ACTH, median level 28 pg/ml, interquartile range (IQR) 14–59 pg/ml; fasting glucose, 100 (91–113) mg/dL; insulin, 15.7 (7.57–24.45) mU/ml; fT(4), 1.17 (1.05–1.4) ng/dL; TSH, 1.70 (0.91–2.90) mIU/L; total cholesterol, 209 (170.5–250) mg/dL; LDL-c, 136 (97.7–163) mg/dL; HDL-c, 44 (37.25–50.75) mg/dL; VLDL-c, 24 (17–36) mg/dL; triglycerides, 120.5 (86–165) mg/dL. The median UFC level of the patients was 30 μg/24 h (IQR 16–103). High levels of UFC (>100 μg/24 h) were recorded in 37 patients (24%). Cushing’s syndrome was diagnosed in 14 of the 150 patients (9.33%). Etiologic reasons for Cushing’s syndrome were pituitary microadenoma (9 patients), adrenocortical adenoma (3 patients), and adrenocortical carcinoma (1 patient). CONCLUSION: A significant proportion (9.33%) of patients with simple obesity were found to have Cushing’s syndrome. These findings argue that obese patients should be routinely screened for Cushing’s syndrome. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2010-01 /pmc/articles/PMC2815288/ /pubmed/20126340 http://dx.doi.org/10.1590/S1807-59322010000100003 Text en Copyright © 2010 Hospital das Clínicas da FMUSP |
spellingShingle | Clinical Science Tiryakioglu, Ozay Ugurlu, Serdal Yalin, Serap Yirmibescik, Sibel Caglar, Erkan Yetkin, Demet Ozgil Kadioglu, Pinar Screening for Cushing’s Syndrome in Obese Patients |
title | Screening for Cushing’s Syndrome in Obese Patients |
title_full | Screening for Cushing’s Syndrome in Obese Patients |
title_fullStr | Screening for Cushing’s Syndrome in Obese Patients |
title_full_unstemmed | Screening for Cushing’s Syndrome in Obese Patients |
title_short | Screening for Cushing’s Syndrome in Obese Patients |
title_sort | screening for cushing’s syndrome in obese patients |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815288/ https://www.ncbi.nlm.nih.gov/pubmed/20126340 http://dx.doi.org/10.1590/S1807-59322010000100003 |
work_keys_str_mv | AT tiryakiogluozay screeningforcushingssyndromeinobesepatients AT ugurluserdal screeningforcushingssyndromeinobesepatients AT yalinserap screeningforcushingssyndromeinobesepatients AT yirmibesciksibel screeningforcushingssyndromeinobesepatients AT caglarerkan screeningforcushingssyndromeinobesepatients AT yetkindemetozgil screeningforcushingssyndromeinobesepatients AT kadioglupinar screeningforcushingssyndromeinobesepatients |